This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
This study is looking at whether Olanzapine-samidorphan + exercise can help people with Schizophenia Disorder, schizoaffective disorder, bipolarity I or II, or bipolarity NOS. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to Olanzapine-samidorphan + exercise, but direct benefit is not guaranteed.
The official record suggests in-person participation through a lab, with sites including New York State Psychiatric Institute. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
This study may matter because it is evaluating Olanzapine-samidorphan + exercise in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by New York State Psychiatric Institute. Based on the sponsor name or official registry information, it appears to be a research institute. You should verify the details in the official registry record.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 4. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.